Navigation Links
Alexza to Announce 2010 Year-End Financial Results on Tuesday, March 15, 2011
Date:3/7/2011

f central nervous system conditions.  Alexza's technology, the Staccato® system, vaporizes unformulated drug to form a condensation aerosol that, when inhaled, allows for rapid systemic drug delivery through deep lung inhalation.  The drug is quickly absorbed through the lungs into the bloodstream, providing speed of therapeutic onset that is comparable to intravenous administration, but with greater ease, patient comfort and convenience. (Click here to see an animation of how the Staccato system works.)

AZ-004 (Staccato loxapine) is Alexza's lead program, which is being developed for the rapid treatment of agitation in schizophrenic or bipolar disorder patients.  Alexza has completed and announced positive results from both of its AZ-004 Phase 3 clinical trials and submitted the AZ-004 NDA in December 2009.  In October 2010, the Company received a CRL from the FDA, regarding its NDA for AZ-004.  A CRL is issued by FDA's Center for Drug Evaluation and Research indicating that the NDA review cycle is complete and the application is not ready for approval in its present form.  The Company completed an end-of-review meeting with the FDA in late December 2010.  

The Company believes it has a clear understanding of the issues outlined in the CRL, is developing and executing a plan to address these issues, and currently projects a resubmission of the AZ-004 NDA in July 2011.  

For more information about Alexza, the Staccato technology or the Company's development programs, please visit www.alexza.com.

Safe Harbor Statement

The anticipated news release and conference call will contain forward-looking statements that involve significant risks and uncertainties. Any statement describing the Company's expectations or beliefs is a forward-looki
'/>"/>

SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Alexza Pharmaceuticals Completes End-of-Review Meeting With FDA for AZ-004 (Staccato® Loxapine) NDA
2. Alexza Pharmaceuticals Provides Regulatory Update for AZ-004 (Staccato® Loxapine)
3. Alexza Pharmaceuticals Reports 2010 Third Quarter Financial Results and Provides Business Update
4. Alexza Pharmaceuticals to Announce 2010 Third Quarter Financial Results on November 9, 2010
5. Alexza Pharmaceuticals Reacquires U.S. and Canadian Rights for AZ-004 (Staccato® Loxapine)
6. Valeant Pharmaceuticals Announces That Alexza Pharmaceuticals Has Received a Complete Response Letter for AZ-004 (Staccato® Loxapine) Inhalation Aerosol NDA
7. Alexza Pharmaceuticals Receives Complete Response Letter for AZ-004 (Staccato® Loxapine) NDA
8. Alexzas Staccato® Nicotine Licensed to Cypress Bioscience
9. Alexza Pharmaceuticals to Present at Bank of America Merrill Lynch 2010 Specialty Pharmaceuticals Conference
10. Alexza Pharmaceuticals Appoints Joseph L. Turner to Its Board of Directors
11. Alexza to Announce 2010 Second Quarter Financial Results on Monday, July 26, 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... Virginia , 11. Juli 2014 ... von Kameras für die molekulare Bildgebung, ... hat heute die CE-Zulassung für sein ... CE-Zeichen kann Dilon das Produkt jetzt ... auf den Großteil der europäischen Länder ...
(Date:7/10/2014)... , July 10, 2014  RESMED INC. (NYSE: ... fourth quarter and fiscal year ended June 30, 2014 results ... Exchange market close. A press release with ResMed,s results will ... company will host a webcast to discuss operating results and ... begin at 1:30 p.m. US Pacific Time and the live ...
(Date:7/10/2014)... , July 10, 2014   Ventana Medical Systems, ... announced it has entered into an agreement with Merck ... as EMD Serono in the United States ... collaborate with Merck KGaA,s biopharmaceutical division on the development ... undisclosed target using Ventana,s proprietary diagnostic assays. In alignment ...
Breaking Medicine Technology:Dilon erhält CE-Zulassung für sein Navigator-Gamma-Sondensystem 2ResMed To Announce Fourth Quarter And Fiscal Year-End 2014 Results 2Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 2Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 3
... OncoSec Medical Incorporated (OTCBB:ONCS), which is developing ... to treat solid tumor cancers, today announced that ... and Lakeland Comprehensive Cancer Center in Lakeland, FL ... are screening patients for the Phase II metastatic ...
... International, Inc. (NASDAQ: BDSI ) announced that ... of further litigation in the patent infringement lawsuit previously ... that the case would be stayed pending resolution by ... proceedings and follows the recent rejection by the USPTO ...
Cached Medicine Technology:OncoSec Initiates Two Additional Clinical Sites for Phase II Metastatic Melanoma Trial 2OncoSec Initiates Two Additional Clinical Sites for Phase II Metastatic Melanoma Trial 3OncoSec Initiates Two Additional Clinical Sites for Phase II Metastatic Melanoma Trial 4Federal Court Grants Request by BioDelivery Sciences for Stay of MonoSol Litigation 2Federal Court Grants Request by BioDelivery Sciences for Stay of MonoSol Litigation 3
(Date:7/11/2014)... HealthDay Reporter THURSDAY, July ... HIV who was thought to be cured by immediate and ... levels of the AIDS-causing virus in her bloodstream, disappointed federal ... years old, had remained virus-free even though she stopped taking ... hoped her remission would open the door to a functional ...
(Date:7/11/2014)... Microbiology testing is a highly dynamic and rapidly ... expected to pose the biggest challenge to suppliers in ... to the ongoing spread of AIDS – still the ... factor leading to the upsurge of opportunistic infections, novel ... availability of immunosuppressants, among others. , Market maturity, ...
(Date:7/11/2014)... The report, “Specialty Synthetic Fibers & Glass ... 2018,” defines and segments the specialty synthetic fibers ... forecast of the volumes and values of types ... aramids, UHMW Polyethylene, carbon fiber, partially oxidized polyacrylonitrile ... PBO fiber, and liquid crystal polymer fiber and ...
(Date:7/11/2014)... 2014 Datalogic brings a new and ... hospital wide. With their new Gryphon GD4400 ... like the devastating MRSA, which claimed 5,500 lives, becomes ... 2D and the Gryphon GM4400-HC 2D readers can ... even read barcodes off of troublesome LCD monitors, smartphones, ...
(Date:7/11/2014)... 2014 Operators and owners ... in fuel costs now that model 2019 ... GHG standards are phasing in 2014-2018 ... themselves to install new features into their ... technologies , 2.    Efficient driveline components which reduce ...
Breaking Medicine News(10 mins):Health News:Mississippi Girl Thought Cured of HIV Shows Signs of Infection 2Health News:Mississippi Girl Thought Cured of HIV Shows Signs of Infection 3Health News:World Virology and Bacteriology Testing Sector Discussed in Comprehensive VPG Research Report Published at MarketPublishers.com 2Health News:World Virology and Bacteriology Testing Sector Discussed in Comprehensive VPG Research Report Published at MarketPublishers.com 3Health News:Specialty Synthetic Fibers & Glass Fiber Market Poised to Reach $20.1 Billion at a CAGR of 5.2% by 2018 – Report by MarketsandMarkets 2Health News:Specialty Synthetic Fibers & Glass Fiber Market Poised to Reach $20.1 Billion at a CAGR of 5.2% by 2018 – Report by MarketsandMarkets 3Health News:Specialty Synthetic Fibers & Glass Fiber Market Poised to Reach $20.1 Billion at a CAGR of 5.2% by 2018 – Report by MarketsandMarkets 4Health News:Stop Spreading Disease with the New Disinfectant-Ready Bar Code Scanner 2Health News:Stop Spreading Disease with the New Disinfectant-Ready Bar Code Scanner 3Health News:LeaseQ Agrees the Latest Round of Greenhouse Gas Rules Could Increase the Cost of Truck Acquisition and Maintenance 2Health News:LeaseQ Agrees the Latest Round of Greenhouse Gas Rules Could Increase the Cost of Truck Acquisition and Maintenance 3
... on mountain biking it is observed that it could decrease ... Innsbruck, Austria,// presented his findings of a study that looked ... 30 non-bikers took part in the study. An extreme biker ... a day, six days a week, and more than 3,000 ...
... good coping style helps women to deal positively with breast ... a difference in the fight against cancer. Researchers in the ... that stress, mental outlook and coping style are all relevant ... ,They found that up to 44 per cent ...
... than conventional treatment for managing asthma attacks. Several ... cells known eosinophils increase// in the airways. Researchers ... targeting this build up of eosinophils in sputum ... attack. ,The conventional treatment consists of ...
... that doctors should use lower thresholds when treating high ... minorities.// Researchers at St George's Hospital, Georgia have carried ... of various ethnic origins, looking at their heart disease ... African origin have the lowest risk of heart disease, ...
... is observed that a drug used to treat inflammation ... meningitis. Dexamethasone is an effective steroid when given with ... diagnosed with bacterial meningitis is high, especially in patients ... Center in Amsterdam conducted a study to determine if ...
... According to a new study, researchers have observed that ... year after angioplasty had a decreased risk of problems. ... called a stent into a blocked coronary artery.// It's ... However, one complication that often occurs when such percutaneous ...
Cached Medicine News:
Alkaline phosphatase FS (DGKC). For determination of alkaline phosphatase (ALP) in serum or plasma. For Hitachi 717. Controls: Trulab N and Trulab P....
Intended for the quantitative determination of alkaline phosphatase activity in serum or plasma. Kinetic reaction. 405 nm wavelength. 830 U/L at 30C linearity. Single vial, dry powder reagent....
Auto LDL-Cholesterol, automated analyzer test kits....
Storage temperature: 2 - 8C, linearity: 0 - 25 mg/dL, expected value: male: 3.5 - 7.0 mg/dL and female: 2.5 - 6.0 mg/dL. Available with calibrator and number of test 500....
Medicine Products: